AI assistant
Moderna, Inc. — Director's Dealing 2020
Jan 29, 2020
30610_dirs_2020-01-29_be5669ff-738c-4354-b9de-efa94d276997.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-01-27
Reporting Person: Kim Lorence H. (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-01-27 | Common Stock | S | 23805 | $23.01 | Disposed | 1336705 | Direct |
| 2020-01-28 | Common Stock | S | 900 | $23.37 | Disposed | 1335805 | Direct |
Footnotes
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.10 to $23.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.